Novocure has obtained FDA clearance for the new head flexible electrode transducer arrays for use with Optune Gio, a wearable for treating glioblastoma. The company plans to transition US users to the improved arrays by mid-2025, aiming to enhance patient comfort and treatment effectiveness.